Drug-drug interactions

Drug-drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have bee...

Full description

Saved in:
Bibliographic Details
Other Authors: Kim, Dong Hyun (Editor)
Format: Books Print Book
Language:English
Published: Basel, Switzerland : Mdpi AG, 2021.
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000nam a22000005a 4500
001 in503314847
005 20240613153500.0
008 240425s2021 sz 000|0 eng d
020 |a 9783036520353  |q (hardcover) 
020 |a 303652035X  |q (hardcover) 
082 4 |a 615  |2 23 
100 1 |a Kim, Dong Hyun,  |e editor. 
245 1 0 |a Drug-drug interactions /  |c edited by Dong Hyun Kim and Sangkyu Lee. 
260 |a Basel, Switzerland :  |b Mdpi AG,  |c 2021. 
300 |a 242 pages ;  |c 25 cm 
336 |a text  |b txt  |2 rdacontent 
337 |a unmediated  |b n  |2 rdamedia 
338 |a volume  |b nc  |2 rdacarrier 
500 |a "Printed edition of the special issue published in Pharmaceutics"--Cover. 
520 0 |a Drug-drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb-drug or food-drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions. 
650 0 |a Drugs. 
650 0 |a Drug interactions. 
650 0 |a Drugs  |x Side effects. 
949 |a CCL  |b CadNF  |c 615 Ki  |d i  |e 39241503820388  |f 772844  |g ddc  |i Library Binding  |j 06/14/2024 
999 |a 489828